Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene J J, Calvieri S, Tosti A, Prens E, Guarrera M, Kanojia P, He W, Kaufman K D
Skin Study Center-Skinterface, Tournai, Belgium.
Br J Dermatol. 2000 Oct;143(4):804-10. doi: 10.1046/j.1365-2133.2000.03780.x.
The growth of scalp hair is a cyclical process of successive phases of growth (anagen) and rest (telogen). In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i.e. increased hair density).
The current study used a phototrichogram methodology to assess the effect of finasteride on the phases of the hair growth cycle.
PATIENTS/METHODS: Two hundred and twelve men, age 18-40 years, with androgenetic alopecia were randomized to receive finasteride 1 mg daily or placebo for 48 weeks. At baseline and at 24 and 48 weeks, macrophotographs were taken to measure total and anagen hair count in a 1-cm(2) target area of the scalp.
At baseline, mean total and anagen hair counts in the finasteride group were 200 and 124 hairs, respectively (% anagen = 62%) and the anagen to telogen ratio was 1.74 (geometric mean). In the placebo group, the respective values were 196 and 119 hairs (% anagen = 60%) and 1.57. At week 48, the finasteride group had a net improvement (mean +/- SE) compared with placebo in total and anagen hair counts of 17.3 +/- 2.5 hairs (8.3% +/- 1.4%) and 27.0 +/- 2.9 hairs (26% +/- 3.1%), respectively (P < 0.001). Furthermore, treatment with finasteride resulted in a net improvement in the anagen to telogen ratio of 47% (P < 0.001). In this study, treatment with finasteride 1 mg day(-1) for 48 weeks increased both total and anagen hair counts, and improved the anagen to telogen ratio.
These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. These data support that finasteride treatment results in favourable effects on hair quality that contribute to the visible improvements in hair growth observed in treated patients.
头皮毛发的生长是一个由生长（生长期）和休止（休止期）连续阶段组成的周期性过程。在之前针对雄激素性脱发男性的临床试验中，非那雄胺治疗可增加特定区域的头皮毛发数量（即增加毛发密度）。
本研究采用毛发照像术方法评估非那雄胺对毛发生长周期各阶段的影响。
患者/方法：212名年龄在18至40岁之间的雄激素性脱发男性被随机分为两组，分别接受每日1毫克非那雄胺或安慰剂治疗，为期48周。在基线、24周和48周时，拍摄头皮1平方厘米目标区域的宏观照片，以测量总毛发数量和生长期毛发数量。
在基线时，非那雄胺组的平均总毛发数量和生长期毛发数量分别为200根和124根（生长期毛发百分比 = 62%），生长期与休止期毛发数量之比为1.74（几何平均数）。在安慰剂组中，相应数值分别为196根和119根（生长期毛发百分比 = 60%）以及1.57。在第48周时，与安慰剂组相比，非那雄胺组的总毛发数量和生长期毛发数量净增加分别为17.3±2.5根（8.3%±1.4%）和27.0±2.9根（26%±3.1%）（P<0.001）。此外，非那雄胺治疗使生长期与休止期毛发数量之比净提高了47%（P<0.001）。在本研究中，每日服用1毫克非那雄胺治疗48周可增加总毛发数量和生长期毛发数量，并改善生长期与休止期毛发数量之比。
这些数据提供了直接证据，表明每日1毫克非那雄胺可促进毛发转化为生长期。这些数据支持非那雄胺治疗对毛发质量有积极影响，这有助于解释在接受治疗的患者中观察到的毛发生长明显改善。
